Webinar: Accelerating hepatitis C elimination in the US

On Tuesday 25 June, the World Hepatitis Alliance (WHA) hosted a webinar to discuss scaling up efforts to achieve hepatitis C elimination in the US. 

Co-chaired by Rachel Halford, President of WHA and Ronni Marks, Director of theHepatitis C Mentor and Support Group, speakers included: 

  • Jordan Akerley, Strategic Director, End Hep C SF 
  • Dylan Moore, Director, VEN Centers 
  • Daniel Raymond, Director of Policy, National Viral Hepatitis Roundtable 
  • Dr Norah Terrault, Chief of Gastroenterology & Hepatology at Keck Medical Center, University of Southern California 

The webinar was convened following the introduction of the Cure Hepatitis C Act in Congress, which proposes a 5-year programme to accelerate hepatitis C diagnosis and treatment. The bill has been introduced as hepatitis C treatment rates have stabilised at levels below those necessary to achieve WHO elimination goals, with many innovations not reaching the 2.2 million Americans living with hepatitis C. The webinar explored challenges facing the bill and next steps to build support in Congress. 

A key innovation that has the potential to improve access to testing for many is point-of-care testing. The updated AASLD guidelines for hepatitis C testing were presented, which incorporate this as a critical component of a simplified testing algorithm. Speakers also highlighted how the point-of-care testing was being used in practice, through mobile screening clinics, to improve access.  

During the event, there was an emphasis on addressing challenges with linkage to hepatitis C testing and treatment through working with people with lived experience and community-based organisations.  

They can reach communities that are often underserved by health systems by co-creating solutions that are rooted in lived experience.  

The webinar highlighted that while there are still many challenges to address, all stakeholders have a role to play in scaling up access to services to achieving hepatitis C elimination in the US.  

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close